
{
  "documentMetadata": {
    "title": "Gastric/Duodenal Ulcer, Helicobacter pylori",
    "lastUpdated": "2022-08-31",
    "sourceFile": "syndromes/intra-abdominal/Gastric_Duodenal Ulcer, Helicobacter pylori.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 2,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Duodenal ulcer or gastric ulcer.",
        "Associated with gastric cancer, MALT lymphoma; not secondary to NSAIDs.",
        "Treatment guidelines all moving to quadruple therapy due to increasing resistance: AGA guidelines: Am J Gastroenterol 112:212 2017; Maastricht Consensus Report Gut 66:6 2017; Toronto Guidelines Gastroenterology 151:51, 2016"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Helicobacter pylori"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Diagnosis"
    },
    {
      "type": "list",
      "items": [
        "Stool antigen-monoclonal enzyme immunoassay (EIA) >90% sensitive & 92% specific (Am J Gastroenterol 101:1921, 2006).",
        "Antibiotics, proton pump inhibitors (PPIs) and bismuth subsalicylate (Pepto-Bismol) can interfere with the accuracy of these tests.",
        "Test 2-4 weeks after stopping antibiotics, 2 weeks after stopping PPI or bismuth.",
        "PCR for H. pylori is available in some centers. J Clin Micro.59:e03040 2021",
        "PCR typing (predicting resistance to clarithromycin) [J Clin Micro.59:e03040 2021] or culture with susceptibilities also available in some centers",
        "Other tests:",
        "If endoscoped, rapid urease + histology + culture",
        "Urea breath test, but some office-based tests underperform (Clin Infect Dis 48:1385, 2009).",
        "Test of cure: Repeat stool antigen and/or urea breath test >8 weeks post-treatment",
        "Antibody tests (H. pylori serology) are positive in both active and distant infection and will remain positive even if cure successful."
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Treatment should be guided by susceptibility testing, where available. PCR typing of clarithromycin resistance now available in some centers; J Clin Micro.59:e03040 2021.",
        "All regimens are po",
        "Duration of therapy for all regimens: 14 days"
      ]
    },
    {
        "type": "nestedContent",
        "content": [
            {
                "type": "paragraph",
                "text": "Options for first line therapy:"
            },
            {
                "type": "nestedContent",
                "content": [
                    {
                        "type": "paragraph",
                        "text": "Bismuth quadruple (PBMT) 4-drug regimen (administer all):"
                    },
                    {
                        "type": "list",
                        "items": [
                            "Proton pump inhibitor (multiple options, see Comments below)",
                            "Bismuth subsalicylate 262-525 mg qid or bismuth subcitrate 120-300 mg qid",
                            "Metronidazole 250 qid or 500 mg tid-qid",
                            "Tetracycline 500 mg qid (Note: do not substitute doxycycline; ref Dig Dis Sci 2019;64:2893)"
                        ]
                    }
                ]
            },
            {
                "type": "nestedContent",
                "content": [
                    {
                        "type": "paragraph",
                        "text": "Non-Bismuth quadruple (PAMC) 4-drug regimen (administer all):"
                    },
                    {
                        "type": "list",
                        "items": [
                            "Proton pump inhibitor (multiple options, see Comments below)",
                            "Amoxicillin 1000 mg bid",
                            "Metronidazole 500 mg bid (could substitute Tinidazole 500 mg bid)",
                            "Clarithromycin 500 mg bid (Note: do not substitute azithromycin)"
                        ]
                    }
                ]
            },
            {
                "type": "nestedContent",
                "content": [
                    {
                        "type": "paragraph",
                        "text": "New single tablet combination formulations:"
                    },
                    {
                        "type": "regimen",
                        "regimenData": {
                            "intent": "treatment",
                            "components": [
                                {"drug": "Talicia (Delayed release capsules containing: omeprazole magnesium 10 mg + amoxicillin 250 mg + rifabutin 12.5 mg)"}
                            ],
                            "durationDetail": {
                                "fixedDuration": "14 days"
                            },
                            "notes": "Dosage: 4 caps with food q8h x 14 days"
                        }
                    },
                    {
                        "type": "regimen",
                        "regimenData": {
                            "intent": "treatment",
                            "components": [
                                {"drug": "Pylera (bismuth subcitrate potassium 140 mg + metronidazole 125 mg + tetracycline 125 mg)"}
                            ],
                            "notes": "Dosage: 3 capsules po after meals and h.s. plus omeprazole 20 mg after breakfast and h.s."
                        }
                    }
                ]
            }
        ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "For patients that fail above regimens",
        "Recommended options (all po):",
        "Bismuth quadruple (PBMT) as above under Primary Regimens",
        "Levofloxacin containing therapy which is usually PAL:",
        "Proton pump inhibitor (multiple options, see Comments below)",
        "Amoxicillin 1000 mg bid",
        "Levofloxacin 500 mg once daily",
        "Option restricted to patients that have failed at least 3 recommended options:",
        "Proton pump inhibitor (multiple options, see Comments below)",
        "Amoxicillin 1000 mg bid",
        "Duration of therapy for all is 14 days.",
        "Evolving alternative using new potent potassium competitive acid blocker: Vonoprazan",
        "Vonoprazan available in Japan and elsewhere, but not in the U.S.",
        "Vonoprazan combined with clarithromycin + amoxicillin is reported to eradicate H. pylori in over 90% of the patients (Intern Med. 2020; 59: 153)"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Choice of treatment regimen should be guided by resistance patterns and prior history of antibiotic usage.",
        "Options not recommended as first line therapy due to emerging resistance and low rates of clinical success:",
        "Sequential non-bismuth quadruple therapy: PPI + Amoxicillin followed by triple therapy with PPI, Metronidazole and Clarithromycin",
        "Triple therapy: PPI + amoxicillin + either Metronidazole or Clarithromycin"
      ]
    },
    {
      "type": "header",
      "level": 2,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Talicia: Rifabutin-based triple therapy (RCT) (Ann Intern Med 2020;172: 795)",
        "Proton pump inhibitors (PPIs). Any of these PPIs may be used. Each considered therapeutically equivalent:",
        "Omeprazole 20 mg bid",
        "Lansoprazole 30 mg bid",
        "Esomeprazole 20 mg bid",
        "Pantoprazole 40 mg bid",
        "Rabeprazole 20 mg bid",
        "Prevalence of pretreatment resistance is increasing, especially to Clarithromycin (Antimicrob Agts Chemother 61: e02530 2017).",
        "Comparative reviews of treatment options (Postgrad Med 128:152,2016; Medical Letter 2018;60:13--includes estimated expense).",
        "All regimens primarily based on H. pylori. Treatment Guideline from the American College of Gastroenterology (Amer J Gastroenterol 2017; 112:212)."
      ]
    }
  ]
}
